BRUKINSA is the only BTK inhibitor
recommended by NICE and accepted by SMC
in CLL, WM and R/R MZL*1–9
*It is only recommended if the company provides it according to the commercial agreement or PAS arrangement1–3,7–9
DESIGNED TO BE DIFFERENT
by minimising off-target effects in the treatment of B-cell malignancies10–13
Proven efficacy regardless of line of
therapy, genetic status and patient
populations14-17
A consistent safety profile
demonstrated across B-cell
malignancies for over 5 years17-20
Unmatched BTK inhibitor
dosing flexibility20-22